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Abstract
Background: Adolescence is a key period of risk for the emergence of Major Depressive Disorder (MDD). The
prescription of selective serotonin re-uptake inhibitors (SSRIs) for the treatment of depression in adolescents is an
issue of worldwide controversy, and evidence regarding their safety and efficacy is inconclusive. In the UK, NICE
guidelines have recently recommended offering SSRIs to adolescents alongside psychological therapy or on their
own if therapy is refused. Thus, SSRIs are increasingly becoming a major component of treatment for adolescents.
This study qualitatively explored adolescents’ views and experiences of SSRIs within their accounts of engaging in a
psychological therapy for depression, particularly focusing on meanings they attached to medication-use.
Methods: The qualitative study reports data from semi-structured interviews conducted 12-months post-treatment
with 12 adolescents who were clinically referred and treated for depression as part of the IMPACT trial. The
interviews were analysed using Thematic Analysis.
Results: Four themes were identified: ‘a perceived threat to autonomy’, ‘a sign of severity’, ‘a support, not a
solution’, and ‘an ongoing process of trial and error’.
Conclusions: This study highlights the value of bringing adolescents’ voices into the broader debate on the use of
antidepressants in their age group and in the development of future guidelines. Future implications for research
and clinical practice are discussed.
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Background
The safety and efficacy of antidepressants for adolescents
is an issue of ongoing worldwide controversy due to
concerns about elevated risk of self-harm and suicidal
behavior [1, 2]. For over a decade, numerous studies
have examined the safety and efficacy of Selective Sero-
tonin Re-Uptake Inhibitors (SSRIs) in adolescents, but
results have been conflicting [see 1]. A recent systematic
review and meta-analysis of clinical trials for several
SSRIs found that serious risks, including suicide and
aggression, were underreported and the extent of poten-
tial harm is not always discernable [3]. Still, prescription
of antidepressants for under 19’s increased worldwide
from 2005 to 2012 [4]. In the UK, first-ever prescriptions
of antidepressants for 3–17-year-olds approximately
doubled between 2006 and 2015 [5].
The National Institute for Health Care and Excellence
(NICE) makes recommendations for treatment in the
UK based on systematic reviews of best available evi-
dence [6]. For adolescents presenting with
moderate-to-severe depression, previous guidelines rec-
ommended an evidence-based psychological therapy as
first line treatment and cautioned against prescribing an-
tidepressants unless the adolescent is unresponsive to
psychological therapy, in which case they recommended
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Fluoxetine, a Selective-Serotonin Re-Uptake Inhibitor
(SSRI), in addition to psychological therapy [6]. The 2015
amendment recommended offering combined psycho-
logical therapy and Fluoxetine as an alternative first line of
treatment. SSRIs can also be offered on their own if psy-
chological therapies are declined, albeit with close moni-
toring. These amendments could mean that more
adolescents in the UK will be offered antidepressants and
potentially at an earlier stage of treatment. A recent study
suggests that SSRIs are being prescribed in the absence of
psychological therapies, contrary to NICE recommenda-
tions; at least 19% of 465 adolescents were prescribed
SSRIs prior to beginning psychological treatment [7].
The rising prescribing trends, aforementioned pre-
scribing practices, and the amendment in guidance all
suggest that antidepressants are increasingly becoming a
major component of treatment for adolescents. Further,
the inconclusive evidence regarding safety and efficacy
of antidepressants highlights the need to better under-
stand the impact of these medications on adolescents.
Developing an understanding of the impact of antide-
pressants that is grounded in adolescents’ perspectives
and narratives can offer new insight into current pre-
scribing practices and the broader debate around anti-
depressant use, especially given that they are the main
stakeholders in treatment.
Antidepressant use in adolescents has been extensively
researched (e.g.[1, 8, 9]). However, only a small number
of studies have focused on adolescents’ own understand-
ing and interpretation of antidepressants as well as their
subjective experience of the effects [10–13]. The avail-
able literature on antidepressants, and psychiatric medi-
cation more broadly, suggests that adolescents attribute
different meanings to medication, which could coincide
with developmental issues pertinent to adolescence, such
as identity formation, autonomy, and social acceptance
[10–16]. For instance, adolescents in one study describe
hiding their medication use due to feelings of shame and
differentiation from peers, stating that it marked them
as ‘defective’ [15]. In other studies, adolescents have re-
ported that they view medication use as contradictory to
their identity as ‘normal’ and ‘autonomous’ teenagers,
and that this can act as a barrier to accepting and adher-
ing to treatment [10, 12, 15]. One study found that ado-
lescents felt resistant to even seeking help for depression
due to fear of being prescribed medication [10].
Together, these studies highlight the importance of ex-
ploring personal meanings that adolescents may attri-
bute to antidepressant medication throughout the
treatment process, and how these meanings impact not
only their acceptance and adherence to the treatment,
but also their developing sense of self. Further, for ado-
lescents who choose to take it, medication is a daily and
possibly important part of the experience of depression
and treatment. This study therefore aimed to qualita-
tively explore adolescents’ views and experiences of SSRI
medication within in their accounts of overcoming de-
pression; specifically, to identify patterns of meaning that
these adolescents attribute to medication within their
broader experience of depression and treatment.
Methods
Setting
This study drew on interviews with adolescents who par-
ticipated in Improving Moods with Psychoanalytic and
Cognitive Therapies (IMPACT), a randomized controlled
superiority trial which compared the effectiveness of
three psychological therapies for adolescent depression
(see [17, 18]). The study recruited 470 adolescents aged
11–17 years with a diagnosis of Major Depressive Dis-
order (MDD) from 15 Child and Adolescent Mental
Health Services (CAMHS) across three UK regions. Ad-
olescents were randomly allocated to one of three man-
ualized treatments: Cognitive Behavioral Therapy (CBT),
Short Term Psychodynamic Psychotherapy (STPP), and
Brief Psychosocial Intervention (BPI). Adolescents were
offered SSRIs during and post-treatment in combination
with the allocated therapy as recommended by NICE
guidelines. IMPACT-My Experience (IMPACT-ME), a
qualitative, longitudinal study, took place alongside IM-
PACT. Interviews were conducted with adolescents par-
ticipating in the trial before therapy (baseline), at the
end of therapy, and one year after (follow-up) see [19].
Data collection and sampling
The current study drew on follow-up data from the
‘Thinking back about therapy’ interview, a
semi-structured schedule which invites adolescents to
reflect on their experience of overcoming depression
soon after therapy ended. Interviews were carried out by
research psychologists with additional training in
in-depth interviewing and lasted between 30 and 90min.
However, medication was not the primary focus of the
interview. Therefore, any mention of medication was ei-
ther in response to a specific question related to medica-
tion, ‘was medication ever discussed with you?’ or
volunteered by the adolescent.
Interviews with all 70 adolescents who took part in the
IMPACT-ME study were first reviewed. As per the
current study’s aim to identify patterns of meaning that
are attributed to medication, adolescents who gave a yes
/ no answer to the interviewer’s question but did not ex-
pand the discussion beyond a single statement or did
not elaborate beyond logistical information (e.g. when
medication was suggested, which medication they took,
dosages) were excluded. This resulted in a sample of 12
interviews in which adolescents spoke about their views
and experiences of being offered medication and/or of
Maroun et al. BMC Psychiatry          (2018) 18:374 Page 2 of 11
taking medication. Given that this is a relatively
under-explored topic, the accounts of both adolescents
who had and had not taken medication were included in
the sample.
Participants
The 12 adolescents (10 female, 2 male) were 13–18 years
old at baseline. All sought and received treatment as part
of IMPACT and met diagnostic criteria for
moderate-to-severe unipolar depression at time of re-
cruitment, as assessed by Kiddie-SADs [20]. Exclusion
criteria were generalized learning difficulties, pregnancy,
primary diagnosis of bipolar Type 1, schizophrenia, per-
vasive developmental disorder, and eating disorders.
Two had received treatment in the STPP arm, five in the
BPI arm, and five in the CBT arm. Three adolescents
expressed their views about medication despite not hav-
ing been offered it, three had refused to take medication
when offered, and six had taken medication – four of
whom had stopped. Of the adolescents who took medi-
cation, three of the adolescents had been prescribed
prior to being recruited and receiving psychological
treatment in the study. When examining their baseline
characteristics, no differences were identified between
this sub-group and the complete set of participants in
the IMPACT-ME study, other than a slightly lower pro-
portion of young people in the STPP arm of the study.
Study design
The current study employed a qualitative design to ex-
plore the sections of the interviews in which adolescents
discussed medication with the aim of obtaining an
in-depth, nuanced account, emphasizing adolescents’
personal views and/or experiences of medication whilst
also drawing broader patterns of meaning across inter-
views. To facilitate this, interviews were analyzed using
thematic analysis (TA), a flexible method of qualitative
analysis that allows researchers to actively identify,
analyze, and report patterns of meaning in data, while
providing a detailed and rich account of themes [21].
Following Braune and Clarke’s [21] six-phase ap-
proach to TA, ‘familiarization’ with the data was
achieved by listening to audio-recordings and reading
entire transcripts to grasp contextual details of ado-
lescents’ broader narratives, noting initial ideas about
the data. In phase two, the first author coded areas
that discussed medication by systematically identifying
and highlighting interesting features and labelling
them according to their content. Each extract was
coded with as many codes as possible until a list of
codes had been generated. In phase three, the author
identified patterns in the codes across the whole data-
set and grouped them into potential themes via
mind-map, whereby different combinations of codes
were arranged and re-arranged until candidate themes
and their sub-themes had been devised. Phase four
involved refining identified themes in a recursive
process; coded data extracts were tabulated under
themes and were then read together under each
theme to determine whether they adequately and co-
herently captured data patterns and to ascertain
whether themes were sufficiently supported. After-
wards, the author re-read the interviews to determine
whether themes reflected the data and captured an
overall picture of meanings adolescents attributed to
medication. At each stage the first author discussed
and refined overarching themes and sub-themes with
the co-authors. Extracts were re-coded again and any
data missed in previous phases were added under
identified themes. In phase five, a detailed analysis
identified the over-arching message for each individ-
ual theme in relation to research aims, with attention
to nuances while still highlighting broader ‘story’ that
the combined themes tell about the data. Finally, each
theme was named and given a concise definition de-
scribing its content.
Trustworthiness and credibility of the analysis
Braune and Clarke’s [21] 15-point-criteria for conducting
‘good’ thematic analysis were followed, with a particular
emphasis on trustworthiness, credibility, transferability,
dependability, and confirmability [22]. Throughout the
process, the research team took a position of reflexivity
[23], continuously acknowledging and evaluating the im-
pact of their own perceptions, experiences, interests, and
background. Interpretations of data were discussed with
co-authors and examined by peers and necessary
changes were made. Further, the data was iteratively
coded three times. A journal was used to document and
review thought progression, decisions, and discussions.
An audit trail documented how data was coded and
grouped into themes. The research team attempted to
‘stay close to the data’ during analysis and used direct
quotes from adolescents when reporting findings to
allow readers to check the analysis against original ac-
counts. Additionally, information about the study setting
and adolescents’ individual contexts were incorporated
into write-up to aid transferability.
Results
Four interrelated themes were identified in relation to
the study aim. Three of these themes were central across
the entire dataset: ‘a perceived threat to autonomy’, ‘a
sign of severity’, ‘a support, not a solution’. One theme
was specifically salient to adolescents who had taken
medication: ‘an ongoing process of trial and error’. These
themes are reported along with their respective
sub-themes (see Fig. 1).
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Theme 1: ‘A perceived threat to autonomy’
For some adolescents, medication seemed to be a threat
to their sense of autonomy. Taking medication appeared
to challenge their view of themselves as independent
and free from external control. This theme was charac-
terized by two interconnected sub-themes: ‘a fear of de-
pendency’ and ‘a desire for self-determination’. These
adolescents either never sought medication, refused to
take it when offered, or took it and stopped. For all these
adolescents, this perception had implications for
whether they took medication as well as adhered to it.
‘A fear of dependency’
A fear of dependency was present in many adolescents’
narratives—whereby taking medication seemed to de-
marcate a forfeit of their independent functioning to an
‘added chemical’ in order to regulate mood and manage
depression.
Adolescents spoke about how taking a daily pill to
manage their depression can be daunting. Talia, who
took medication, described how relying on medication
every day to keep her mood stabilized was simultan-
eously a source of anxiety and confusion:
“It’s annoying I have to take these pills every day…if I
forget it could be bad(...)It’s unnerving when you’re
feeling happy and having a side thought going yeah
but are you happy or is it just added chemicals
making you feel happy?” - (Talia)
For Talia, taking medication led her to question her abil-
ity to function without it and interfered with her percep-
tion of her emotions as being her own. She recalled her
decision to stop taking medication because she felt it
was a risk worth taking in exchange for being free from
having to rely on it daily, even if this meant ending up in
hospital:
“It wouldn’t be worth having to take pills every single
day just to stop that one day coming around every
now and again(...)so I was like I might as well stop, see
what happens(...)worst comes to worse I might end up
in hospital again” - (Talia)
Adolescents also described a fear of being physically
dependent on anti-depressants. For example, for Ma-
thilda, this seemed to be associated with a fear of experi-
encing a difficult withdrawal, making her hesitant to
stop taking medication:
“I didn’t wanna depend on it too much …but at the
same time I was worried about coming off it, especially
doing A-levels cos it’s a stressful time” - (Mathilda)
Whereas, for Elizabeth, these fears, which arose from
family experience, contributed to her decision not to
take medication:
“My Mum’s been on the medications and I don’t really
wanna go on it cause I’ve seen her try and come off it.
It’s taken her three or four attempts before she could
come off it, so I said ‘I don’t wanna be dependent on
it’.” - (Elizabeth)
‘A desire for self-determination’
This sub-theme delineates a simultaneous desire to
manage depression via one’s own will, whereby change
has to be self-induced and on one’s own terms.
Many adolescents who talked about their fear of de-
pendency also expressed a desire to overcome their
Fig. 1 Final thematic map: themes, sub-themes, and features
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depression by their own will and self-determination: “I
want to get over this myself” (Elizabeth). Talia, who took
medication, spoke about wanting to be free from de-
pending on it to manage her mood and wanting to re-
gain her sense of self-determination:
“I’m capable of making myself happy(...)so why am I
having to take extra chemicals in my body that can
cause these side effects when I could just work on
myself and do it that way?(...) like I need to stop this. I
was getting to a point where it’s like I can kind of take
care of myself.” - (Talia)
Talia describes medication as providing a lift in mood at
the price of enduring unwanted side effects, thus impin-
ging on a sense of bodily control in an undesirable way.
For Talia, this seemed to elicit a desire to regain a sense
of control over her body, which, together with her belief
that she can make herself happy, contributed to her de-
cision to stop medication. For Callum, his preference to
overcome his depression by his own means led to his de-
cision not to take medication at all:
“I wouldn’t even wanna take medication. I’d rather
just deal with it my way.” - (Callum).
Overall, the need for medication is understood here as a
sign of an inability to cope with depression via self-
determination. Further, adolescents seemed to have a
shared perception that taking medication would take
away a degree of control over their bodies and impinge
on their ability to take care of themselves.
Theme 2: ‘A sign of severity’
Almost all adolescents identified a particular point at
which they deemed or would deem medication to be ne-
cessary, referring to how low they perceived their mood
to be and its impact on their functioning.
Medication was seen as necessary when depression
was experienced as particularly severe. The adolescents
who had never considered or had declined taking medi-
cation spoke of how they were not at a point in their de-
pression that warranted its use, “I don’t think my
depression was that serious, so I didn’t take medication”
(Priya). Further, medication seemed to be reserved for a
level of severity that adolescents were able to recognize:
“I think that should be the last resort, I don’t think you
should put everyone on meds because sometimes it’s
not serious for them to be on meds. For me, it was not
that serious” - (Natasha)
Similarly, adolescents who had taken medication re-
ferred to a certain point at which they felt their mood
was so low that they decided its use was necessary for
them to be able to manage. For example, Steven de-
scribed feeling so overwhelmed and trapped by his de-
pression that medication was thought to be a necessary
next step:
“I got prescribed antidepressants because I felt really
down…like this constant feeling of down(...)I’m
depressed in a way that makes me feel like I can’t do
anything about it.” - (Steven)
Lana, who declined medication, recalls that she consid-
ered taking it when her depression was so severe that it
placed her at an acute risk:
“I was actually willing to go to medication for the first
time ever because I was so bad. I was like okay I might
go on an antidepressant(...)That one time I went to
A&E was the only time I was actually resorting--- for
me to actually accept that okay I might actually take
medication I was in a very bad place.” - (Lana)
To Lana, taking medication was only conceivable when
she had to make use of emergency services, denoting it
as an option that is ‘resorted’ to at a time of utmost se-
verity. Thus, for all these adolescents, medication was
viewed as a resource that can be drawn on when depres-
sion was particularly severe and chronic; when they were
feeling particularly at their worst and no longer able to
manage their depression.
However, for some adolescents, medication featured
as a resource only to be drawn on when other options
have been exhausted. For example, Charlotte men-
tioned that medication was only warranted at a time
when other treatments have failed, and it was the last
option available:
“I thought try therapy cause then you see if that works
and if it does it might help me long-term and if that
didn’t work I could always resort to medication”-
(Charlotte)
However, other options were not always described as ac-
cessible because of depression severity. For example,
Leila described experiencing such chronic low mood and
feelings of helplessness that she was unable to manage
on her own or engage with help from professionals, at
which point she was willing to try medication despite
feeling uncertain:
“I mean I think it was just because I was so low that I
couldn’t like benefit from therapy. I was too upset to
even like put anything into action or help myself.” -
(Leila)
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Medication seemed to be a necessary precursor to being
able to access other forms of help. Therefore, these ado-
lescents described medication as the next step when de-
pression felt overpowering and/or nonresponsive to other
forms of help. As such, the perceived need for medication
acted as a point of reference for adolescents whereby they
could gauge not only how severe their depression was, but
also how well they were able to manage it.
Theme 3: ‘A support, not a solution’
The majority of adolescents shared the belief that medi-
cation can play a beneficial role whilst overcoming de-
pression. However, its role was deemed to be facilitative,
whereby adolescents described medication as a form of
additional rather than a solution in its own right. This
theme applied to those who had and had not taken
medication.
Adolescents who had taken medication described it as
playing a key role in their recovery during a time of stag-
nation, by helping them engage in treatment, regain
functioning, and resume pleasurable activities they had
stopped due to depression. However, it was seen as of-
fering something additional alongside therapy rather
than a standalone treatment—described by Leila as
“extra help from something else” and by Steven as “some-
thing to lift mood”. Similarly, Mathilda saw medication
as having a supportive role in recovery, whereby it stabi-
lized mood so that it felt manageable.:
“Therapy was really good, and it helped and probably
medication as well, but that was more about the lack of
safety blanket until I was feeling better. But I think the
main thing was the therapy…just different methods for
coping (...) I knew that if things did go downhill again I
could just go back on medication I suppose.” -(Mathilda)
For Mathilda, medication served as a temporary extra
component and an option that she could fall back on if
needed—particularly at a point of relapse. Further, therapy
and medication were seen here as distinct ways of coping,
although both were described as contributing to recovery.
Similarly, Kayleigh stated that medication allowed her to
better engage in therapy and experience a sense of hope
despite it initially being a difficult decision:
“I was getting better but I needed a final push (...)it was
a tough decision cause I didn’t like taking tablets but I
think looking back now it was the right decision to go on
it (...)I started crawling out of the hole but then once the
medication kicked in it was just like I can actually see
the light at the end.” - (Kayleigh)
For Kayleigh, combining medication with therapy was
described as a turning point in her treatment, whereby
medication offered a different kind of support that she
experienced as essential to her recovery.
Similarly, to those who did take medication, those who
did not talked about how medication might help ease
the burden of depression. However, they expressed a de-
sire to deal with underlying issues, which contributed to
their decision to refuse medication:
“Medication doesn’t solve the problem it just helps you
deal with it a bit more cause at the end of the day
you’re still gonna have to deal with it yourself. Even if
medication takes a bit off the edge…it just kind of
covers the problem” - (Lana)
As such, they tended to see medication as a temporary
way of managing their depression and preferred to en-
hance their own ability to cope, describing this as more
sustainable in the long-term:
“The medications not always gonna be there so I
would just come to terms with myself and stuff.” -
(Callum)
These adolescents also expressed a preference for ther-
apy: “if you just take a tablet, you can’t just expect to get
better straight away. It’s better to talk things out” (Priya),
appearing to believe that it was a more long-term solu-
tion than medication. Natasha, who was offered medica-
tion, but declined, cited this preference as her reason.
Moreover, she expressed a belief that medication could
not help her resolve her difficulties, despite acknowledg-
ing that it might temporarily help her manage her symp-
toms:
“If I got straight away offered medication without
dealing with the real issues, I would have just
refused(...)Medication would make me feel okay, but it
wouldn’t deal with my deeper demons. I think if we
just give someone medication and not give them
opportunity to try and explore and work with their
issues within themselves…It’s just gonna deal with the
problem there and then but it’s not going to help in the
long-term” - (Natasha)
For Natasha, her belief that her depression was linked to
relational difficulties seemed to be a key reason for her
refusal of medication and preference for therapy:
“Me having therapy has helped my life in so much
ways, it’s gonna help my future in the long run. But
if you gave me medication, I would still be battling
with my past, my Dad’s relation, and I would just
be kind of a neutral person, coping with pills.” -
(Natasha)
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Here, medication was described as a temporary method
of coping with low mood, whereby the perceived cause
of depression remains unaddressed.
Thus, adolescents appeared to denote medication as
having the specific role of alleviating low mood, while
therapy was seen as addressing underlying issues. Al-
though all adolescents assigned some value to medi-
cation, whether they took it seemed to be related to
what they felt was the most pertinent to overcoming
their depression. Specifically, adolescents who took
medication described experiencing low mood as over-
powering and debilitating, and thus felt that medica-
tion was a necessary step to take to enable them to
address underlying issues in therapy. Whereas, adoles-
cents who did not take medication, felt they were
functioning well enough and could manage their de-
pression without medication, preferring to deal with
underlying issues in the first instance. Still, they did
see medication as being available to help them cope
with low mood if necessary.
Theme 4: ‘An ongoing process of trial and error’
This theme relates solely to adolescents who had taken
medication. To these adolescents, taking medication was
not a straightforward process, rather, it was an ongoing,
recursive process of trial and error during which they
struggled to find the right type, dosage, frequency, and
length of treatment. For example,
“I was taking anti-depressants for six, seven months,
and then eventually I got to a point, before the psych-
iatrist said I could… I came off medication, but in Oc-
tober I went back onto medication” – (Ada).
Adolescents also described their struggle to cope with
side effects, sometimes having to experiment with differ-
ent types of medication and understand how they af-
fected their bodies:
“we went through different antidepressants then I
chose one I haven’t taken before (…) Dunno I hope
they help but with every anti-depressant there’s a
different side-effect…so interesting to see what the
side-effects of these are (...)Oh [medication 1]…I just
slept constantly(...) and the other ones I just felt
completely numb that’s why I stopped taking
them…”– (Steven)
Adolescents also described the difficulty of gaging
whether to stop taking medication, which induced a
level of anxiety about withdrawal effects. Talia recalled
how her decision to suddenly stop medication caused
concern from her parents and professionals, resulting in
a period of careful monitoring afterwards:
“I was on fluoxetine twice. I was on it for like a year
and then it stopped working and then we tried it
again, like a year or so later and it didn’t have the
same effect as when I started the first time so we
stopped that (...) then I was on citalopram and then
spring this year I was like I don’t wanna take these
anymore so I stopped (...)Mum and dad were worried,
they’re like ‘you ‘can’t just stop taking your
medications”- (Talia)
Thus, for these adolescents, the experience of taking
medication was more than merely receiving a prescription
and taking it. Rather, it was an ongoing process whereby
adolescents wrestled with tough questions relating to the
meaning and potential consequences of medication use.
Discussion
The current study explored the meanings that adoles-
cents attached to SSRI medication within their narratives
of overcoming depression. Four main themes were iden-
tified: ‘a perceived threat to autonomy’, ‘a sign of severity’,
‘a support, not a solution’, and ‘an ongoing process of
trial and error’.
The first theme, ‘a perceived threat to autonomy’ is
consistent with previous studies that have shown that
adolescents who are resistant to medication tend to de-
scribe taking it as inconsistent with being ‘autonomous’
[10, 12, 15]. Adolescence is recognised as a key period
for identity formation whereby individuals strive for au-
tonomy, thus adolescents may view medication as a fur-
ther impingement on their identity as autonomous
individuals [24]. Moreover, some adolescents in this
study associated antidepressant use with being
‘dependent’ and referred to medication as ‘added chemi-
cals’ that are an undesirable means of obtaining happi-
ness, expressing their wish to do so by their own means.
This could indicate some anxiety about what medication
does to their body, but also that medication use could
be perceived as a loss of control over their bodies, espe-
cially at a time when they may be experiencing signifi-
cant biological changes [25]. Furthermore, this theme
was salient for adolescents who had refused to take
medication and those who accepted it then decided to
stop. Thus, this could have implications for whether ad-
olescents seek or accept medication as part of treatment
and whether they adhere to it. Even if antidepressant
treatment is effective, it has limited value if adolescents
do not seek it and adhere to it [1]. A systematic review
found that adolescents’ positive beliefs about their treat-
ment was associated with improved adherence [26].
The second theme, ‘a sign of severity’ showed that
medication was deemed necessary when depression was
perceived and experienced as severe. This aligns with
the NICE recommendations’ stepped care model, which
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indicates that antidepressants should only be prescribed
for adolescents presenting with moderate-to-severe de-
pression [6]. However, all adolescents in this study had
a diagnosis of moderate-to-severe depression, indicat-
ing there may be qualitative differences in ‘severity’.
Adolescents captured this difference, describing a level
of ‘severity’ that warrants antidepressant use, associated
with the experience of depression as too overwhelming
and debilitating, having extremely low mood, and feel-
ing they could no longer manage on their own. These
descriptions have been reported by other adolescents in
previous qualitative research [27, 28], where this ‘over-
whelming’ quality to depression was also prominent.
Moreover, adolescents’ descriptions of feeling too low
to benefit from therapy, feeling trapped by depression,
and being at a dangerous low point are consistent with
previous findings that suggest adolescents are prescribed
antidepressants as a first line treatment when they
present with severe depression or are too reluctant to
initially engage with therapy [29]. Therefore, introducing
antidepressants at an earlier stage in treatment may be
beneficial to some adolescents. This is supported by the
latest NICE guidelines which suggest antidepressants as
a first line treatment in combination with psychological
therapy or on their own if the adolescents do not engage
with psychological therapy [6].
Adolescents’ understanding of the need to take medica-
tion also seemed related to how they perceived their abil-
ity to cope. This ties in with the first theme, which
suggests medication is perceived as a sign of being incap-
able of managing depression via their self-determination.
These two themes may indicate that taking a daily pill to
cope with depression could be perceived by adolescents as
a concrete statement that they are at a particularly low
point, unable to manage without it. As such, these themes
echo the findings of other studies in which adolescents de-
scribed psychiatric medication as a marker of their ‘defect-
iveness’ and or a sign that they are ‘not autonomous’ [10,
12, 15]. Underlying beliefs of being ‘defective’ and
‘dependent’ are also characteristic of depression more gen-
erally [30]. When these meanings are associated with
medication, it is possible that the suggestion of medication
may trigger, or heighten, these beliefs. Given that adoles-
cence is recognized as a developmental stage in which
issues of identity and autonomy are particularly salient,
these beliefs may impact adolescents’ views of them-
selves and have longer term consequences if not ad-
dressed [14]. This highlights the need for further
research and careful consideration when prescribing
antidepressant medication, specifically in relation to
how adolescents’ personal meanings might interact with
relevant developmental issues.
The third theme, ‘a support, not a solution’ is consist-
ent with previous qualitative research with adults where
antidepressants were described as helpful to cope with
and improve low mood, but only a partial or temporary
fix [31, 32] or as not addressing social and psychological
issues that were perceived as causes of depression [33].
However, the current findings indicate that while adoles-
cents seem to assign SSRIs and psychological therapy
distinct roles in treatment, they do not discount medica-
tion as an option. Whether and when adolescents believe
SSRIs to be beneficial to their treatment could be related
to whether they believe alleviating symptoms or address-
ing other psychological or social issues was most pertin-
ent to their recovery. This also links to the previous
theme, where adolescents felt that medication could play
a beneficial role in treatment when depressive symptoms
did not allow them to address underlying issues in ther-
apy. Subsequently, the value adolescents place on the
role of antidepressants in their treatment could be re-
lated to their beliefs about their depression. Although
both adolescents who had and had not taken medication
seemed to share the view that the act of taking antide-
pressants implies that they are not autonomous or that
their depression is particularly severe, they simultan-
eously maintained that medication can play a facilitative
role in treatment. These results are consistent with those
reported in studies with adults, which show that they to
struggle with ambivalent views about antidepressant
medication [32, 34, 35]. These simultaneous beliefs
could create a dilemma for adolescents who are deciding
whether to take medication for the first time, or for
those who are taking medication, whether to stop.
The fourth theme, ‘an ongoing process of trial and
error’ highlights that taking antidepressants can be a dif-
ficult process marked by a continuous struggle to en-
hance benefits and reduce adverse effects. This supports
NICE guidelines’ emphasis on close and continuous
monitoring of adolescents taking antidepressants [6].
However, this theme highlights how frustrating and disil-
lusioning this process can be, potentially heightening
feelings of hopelessness, which are associated with de-
pression [36]. Thus, more holistic support is required in
addition to routine monitoring, holding implications for
both treatment effectiveness and adherence. Addition-
ally, it emphasizes that adolescents may have concerns
about when to stop their medication, what it means to
function without it, or difficult withdrawals—a signifi-
cant issue for adolescents discontinuing antidepressants
[37]. Qualitative studies have found that adults may
choose to remain on antidepressants despite perceiving
that they no longer need them due to fears of with-
drawal, relapse, or lack of support [38, 39].
Together, these four themes highlight how antidepres-
sant treatment can hold complex meanings for adolescents
throughout their experience of overcoming depression
and may have implications for their views of themselves
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and the way they conceptualize their depression. This
aligns with adult literature showing that experiences with
antidepressant use are complex and dynamic, character-
ized by a temporal process of ‘decision-making’ and
‘meaning-making’ where treatment decisions are inter-
linked with the emergence of new self-concepts [32, 40].
Clinical implications
This study holds implications regarding antidepressant
treatment with adolescents. Particularly, it
re-emphasizes that practitioners should involve adoles-
cents in the discussion about risks and benefits of SSRIs
and provide them with the latest information to help
them make informed choices and that antidepressant
treatment should be monitored continuously [6]. These
findings also emphasize that in addition to addressing is-
sues of symptom control, physical tolerability, adher-
ence, and side effects, clinicians should continuously and
actively elicit, address and reflect on the impact of medi-
cation on adolescents’ perceptions of themselves, their
depression, and their quality of life with consideration to
their developmental context. Further, this study supports
the need for better implementing models of shared deci-
sion making (SDM) and involving adolescents as active
partners their antidepressant treatment advocated by
others [41–46].
Strengths and limitations
The current study elucidated meanings grounded in ad-
olescents’ perspectives on antidepressant use, which have
scarcely been explored. Further, it captured specific nu-
ances of meaning and potential commonalities in adoles-
cents’ views and experiences. However, as all the
adolescents sought out, engaged with, and completed
psychological therapy by the time of interview, these
findings may not be representative of those who do not
seek help, drop out of treatment, or do not engage with
therapy and opt for solely taking antidepressant medica-
tion. Adolescents were also interviewed at the final time
point of the IMPACT-ME study and the interviews were
selected only if they spoke about their experience or
feelings about medication—which was not the inter-
views’ primary focus. Therefore, these findings may only
be representative of adolescents who had strong opin-
ions on medication and were invested in expressing their
views and experiences and cannot be extrapolated to all
depressed adolescents. Additionally, meanings were de-
rived from adolescents’ retrospective accounts. Thus, it
is difficult to discern whether and how these meanings
may have shifted over time from initial discussions.
Conclusions
Overall, the current study highlights the value of bring-
ing adolescents’ voices into the broader debate on the
use of antidepressants in their age group and in the de-
velopment of future guidelines. The findings showed
how adolescents’ may attribute highly personal meanings
to antidepressant use, which hold implications for their
view of themselves and their depression, and in turn,
may impact on their treatment decision, their adherence,
their response to medication if it is taken. Hence, the
current study also emphasizes the importance of collab-
oratively exploring these meanings with adolescents
throughout the treatment process in order to enhance
their treatment experience.
The findings of this study also echo previous literature
advocating a shift from questioning whether antidepres-
sants work to questioning whom they work for [44, 47].
They highlight the value of incorporating qualitative re-
search from an adolescent-centered perspective into fu-
ture NICE guidelines as is already the case in relation to
guidelines on ADHD medication use [48]. Future re-
search should explore adolescents’ perspectives of SSRIs
at different stages of treatment, which may provide
insight into how to better support adolescents during
the course of their treatment. Over time it may be pos-
sible to create a valuable body of literature that can be
referred to when making life-changing decisions about
whether to initiate, continue, or discontinue antidepres-
sant treatment with adolescents.
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